FDA Grants New Platform Technology Designation to Krystal's Gene Therapy for Neurotrophic Keratitis

October 16, 2025 - 04:02

Krystal has become the second company to receive the newly established FDA Platform Technology Designation for its innovative gene therapy aimed at treating neurotrophic keratitis. This designation is significant as it recognizes the potential of Krystal's viral vector technology to address unmet medical needs in the field of ophthalmology.

Neurotrophic keratitis is a degenerative disease of the cornea that can lead to severe vision impairment and even blindness if left untreated. The FDA's designation highlights the agency's commitment to facilitating the development of cutting-edge therapies that can improve patient outcomes. By granting this status, the FDA aims to expedite the review process for Krystal's gene therapy, which employs a unique approach to regenerate corneal nerves and restore normal corneal function.

The recognition from the FDA not only underscores the innovative nature of Krystal's technology but also paves the way for further advancements in gene therapies for ocular diseases. As the company moves forward, it anticipates that this designation will enhance its efforts to bring this promising treatment to patients in need.